Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma. [electronic resource]
Producer: 20130220Description: 293-303 p. digitalISSN:- 1097-0142
- Animals
- Antineoplastic Agents -- administration & dosage
- Apoptosis -- drug effects
- Benzoquinones -- administration & dosage
- Bile Duct Neoplasms -- genetics
- Bile Ducts, Intrahepatic -- metabolism
- Cell Line, Tumor
- Cell Survival -- drug effects
- Cholangiocarcinoma -- genetics
- Drug Evaluation, Preclinical
- Female
- G2 Phase Cell Cycle Checkpoints -- drug effects
- Gene Expression Regulation, Neoplastic
- Genomics
- HSP90 Heat-Shock Proteins -- antagonists & inhibitors
- Humans
- Inhibitory Concentration 50
- Isoxazoles -- administration & dosage
- Lactams, Macrocyclic -- administration & dosage
- Liver Neoplasms, Experimental -- chemically induced
- MAP Kinase Signaling System
- Male
- Middle Aged
- Oligonucleotide Array Sequence Analysis
- Rats
- Rats, Sprague-Dawley
- Resorcinols -- administration & dosage
- Transcriptome
- Tumor Burden -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.